Active, Not Recruiting
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy - CA209-451
Updated: 20 September, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Subjects with histologically or cytologically confirmed extensive stage disease SCLC - Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: - Subjects with symptomatic Central Nervous System (CNS) metastases - Subjects receiving consolidative chest radiation - Subjects with active, known, or suspected autoimmune disease are excluded - All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
